New Monoclonal Authorized to Prevent COVID in Immunocompromised People

Retrieved on: 2024-03-22 22:50:07

Tags for this article:

COVID-19 drug development

Monoclonal antibodies

Immunology

AstraZeneca

Tixagevimab/cilgavimab

COVID-19

Post-exposure prophylaxis

Variants of SARS-CoV-2

Cytokine release syndrome

Casirivimab/imdevimab

Bamlanivimab/etesevimab

Click the tags to see associated articles and topics

New Monoclonal Authorized to Prevent COVID in Immunocompromised People. View article details on HISWAI: https://www.medpagetoday.com/infectiousdisease/covid19/109336

Summary

The FDA authorized pemivibart (Pemgarda) for pre-exposure COVID-19 prophylaxis in immunocompromised individuals, relating to drug development, monoclonal antibodies, and immunology, specifically for variant-resistant cases.

Article found on: www.medpagetoday.com

View Original Article